Exagen (XGN) Equity Average (2018 - 2026)

Exagen (XGN) has reported Equity Average for 9 consecutive years, with $15.9 million the latest figure, recorded in Q1 2026.

• Equity Average for Q1 2026 came in at $15.9 million, up 99.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.9 million (up 99.97% YoY), and the FY2025 annual result was $13.5 million, down 16.27% from the prior year.
• Equity Average was $15.9 million for Q1 2026 at Exagen, down from $17.8 million in the prior quarter.
• Over five years, Equity Average peaked at $80.5 million in Q1 2022 and troughed at $8.0 million in Q1 2025.
• Average Equity Average over 5 years is $31.1 million, with a median of $21.3 million recorded in 2024.
• Year-over-year, Equity Average plunged 62.65% in 2025 and surged 99.97% in 2026.
• Over 5 years, Equity Average stood at $49.3 million in 2022, then slumped by 49.11% to $25.1 million in 2023, then tumbled by 55.36% to $11.2 million in 2024, then soared by 58.81% to $17.8 million in 2025, then fell by 10.41% to $15.9 million in 2026.
• Per Business Quant data, the three most recent Equity Average figures were $15.9 million in Q1 2026, $17.8 million in Q4 2025, and $19.6 million in Q3 2025.